
The Divide Between Eli Lilly and Novo Nordisk: A Growing Chasm in the GLP-1 Market
Eli Lilly and Novo Nordisk lead the GLP-1 market, but a growing divide threatens Novo Nordisk's position. Discover the latest quarterly results and implications for the $100 billion market.









